
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (26): 3264-3270.DOI: 10.12114/j.issn.1007-9572.2024.0251
Special Issue: 内分泌代谢性疾病最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2024-04-08
Revised:2024-07-06
Published:2025-09-15
Online:2025-07-22
Contact:
LI Ruibin, WANG Wei
通讯作者:
李瑞斌, 王玮
作者简介:作者贡献:
张宇诺进行数据的收集与整理,数据统计分析,图、表的绘制与展示,撰写论文初稿;李瑞斌负责文章的质量控制与审查,论文的修订;王玮提出文章构思与设计,对文章整体负责。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0251
| 组别 | 例数 | 年龄( | 性别[例(%)] | 收缩压( | 舒张压( | VFA[M(P25,P75),cm2] | SFA[M(P25,P75),cm2] | ||
|---|---|---|---|---|---|---|---|---|---|
| 男性 | 女性 | ||||||||
| 对照组 | 85 | 42.6±12.0 | 41(48.2) | 44(51.8) | 120±6 | 80±6 | 81.9(70.7,89.4) | 114.0(103.0,121.0) | |
| 试验组 | 170 | 56.0±11.8 | 92(54.1) | 78(45.9) | 135±19 | 80±10 | 107.2(85.8,147.2) | 203.6(159.8,241.4) | |
| 检验统计量值 | 8.351 | 0.786a | 9.632 | -0.498 | 9.210b | 18.549b | |||
| P值 | 0.006 | 0.375 | 0.042 | 0.669 | 0.005 | 0.008 | |||
| 组别 | 腰围( | 臀围( | 腰臀比( | 高血压[例(%)] | 高血脂[例(%)] | 冠心病[例(%)] | 脑梗死[例(%)] | 脂肪肝[例(%)] | BMI[M(P25,P75),kg/m2] |
| 对照组 | 89.1±4.6 | 106.6±9.7 | 0.93±0.05 | 0 | 0 | 0 | 0 | 5(5.9) | 22.0(20.8,23.2) |
| 试验组 | 96.1±9.1 | 103.4±7.8 | 0.91±0.09 | 97(57.1) | 65(38.2) | 20(11.7) | 15(8.8) | 42(24.7) | 26.0(23.6,28.6) |
| 检验统计量值 | 8.225 | -0.296 | 1.059 | 28.275a | 13.618a | 10.851a | 7.969a | 12.625a | 14.502b |
| P值 | 0.023 | 0.035 | 0.036 | 0.008 | 0.006 | 0.012 | 0.032 | 0.087 | 0.043 |
Table 1 Comparison of general information between the two groups
| 组别 | 例数 | 年龄( | 性别[例(%)] | 收缩压( | 舒张压( | VFA[M(P25,P75),cm2] | SFA[M(P25,P75),cm2] | ||
|---|---|---|---|---|---|---|---|---|---|
| 男性 | 女性 | ||||||||
| 对照组 | 85 | 42.6±12.0 | 41(48.2) | 44(51.8) | 120±6 | 80±6 | 81.9(70.7,89.4) | 114.0(103.0,121.0) | |
| 试验组 | 170 | 56.0±11.8 | 92(54.1) | 78(45.9) | 135±19 | 80±10 | 107.2(85.8,147.2) | 203.6(159.8,241.4) | |
| 检验统计量值 | 8.351 | 0.786a | 9.632 | -0.498 | 9.210b | 18.549b | |||
| P值 | 0.006 | 0.375 | 0.042 | 0.669 | 0.005 | 0.008 | |||
| 组别 | 腰围( | 臀围( | 腰臀比( | 高血压[例(%)] | 高血脂[例(%)] | 冠心病[例(%)] | 脑梗死[例(%)] | 脂肪肝[例(%)] | BMI[M(P25,P75),kg/m2] |
| 对照组 | 89.1±4.6 | 106.6±9.7 | 0.93±0.05 | 0 | 0 | 0 | 0 | 5(5.9) | 22.0(20.8,23.2) |
| 试验组 | 96.1±9.1 | 103.4±7.8 | 0.91±0.09 | 97(57.1) | 65(38.2) | 20(11.7) | 15(8.8) | 42(24.7) | 26.0(23.6,28.6) |
| 检验统计量值 | 8.225 | -0.296 | 1.059 | 28.275a | 13.618a | 10.851a | 7.969a | 12.625a | 14.502b |
| P值 | 0.023 | 0.035 | 0.036 | 0.008 | 0.006 | 0.012 | 0.032 | 0.087 | 0.043 |
| 组别 | 例数 | HbA1c( | FPG[M(P25,P75),mmol/L] | 空腹C肽( | HDL-C[M(P25,P75),mmol/L] | LDL-C[M(P25,P75),mmol/L] | HOMA-IR[M(P25,P75)] |
|---|---|---|---|---|---|---|---|
| 对照组 | 85 | 5.1±0.5 | 5.0(4.6,5.6) | 2.9±0.9 | 1.5(1.3,1.7) | 2.9(2.5,3.2) | 15.5(11.5,18.5) |
| 试验组 | 170 | 9.2±1.8 | 9.6(7.6,12.0) | 2.1±1.4 | 1.1(0.9,1.4) | 2.9(2.1,3.6) | 20.3(13.2,31.2) |
| t(Z)值 | 14.502 | 26.932a | -5.087 | -1.962a | -0.936a | 6.101a | |
| P值 | 0.006 | 0.042 | 0.036 | 0.038 | 0.120 | 0.043 | |
| 组别 | 血肌酐( | 血尿酸( | TG( | TC( | Nesfatin-1( | Ghrelin( | |
| 对照组 | 76.9±10.7 | 325.2±18.1 | 1.0±0.3 | 4.4±0.7 | 205.23±7.51 | 23.17±1.26 | |
| 试验组 | 72.7±26.6 | 324.8±17.7 | 2.3±1.9 | 4.7±1.4 | 132.52±5.92 | 58.44±8.59 | |
| t(Z)值 | 1.811 | -0.036 | 8.268 | 2.054 | -15.864 | 5.192 | |
| P值 | <0.001 | 0.977 | 0.017 | 0.026 | <0.001 | <0.001 |
Table 2 Comparison of the characteristics of clinical blood indicators between the two groups
| 组别 | 例数 | HbA1c( | FPG[M(P25,P75),mmol/L] | 空腹C肽( | HDL-C[M(P25,P75),mmol/L] | LDL-C[M(P25,P75),mmol/L] | HOMA-IR[M(P25,P75)] |
|---|---|---|---|---|---|---|---|
| 对照组 | 85 | 5.1±0.5 | 5.0(4.6,5.6) | 2.9±0.9 | 1.5(1.3,1.7) | 2.9(2.5,3.2) | 15.5(11.5,18.5) |
| 试验组 | 170 | 9.2±1.8 | 9.6(7.6,12.0) | 2.1±1.4 | 1.1(0.9,1.4) | 2.9(2.1,3.6) | 20.3(13.2,31.2) |
| t(Z)值 | 14.502 | 26.932a | -5.087 | -1.962a | -0.936a | 6.101a | |
| P值 | 0.006 | 0.042 | 0.036 | 0.038 | 0.120 | 0.043 | |
| 组别 | 血肌酐( | 血尿酸( | TG( | TC( | Nesfatin-1( | Ghrelin( | |
| 对照组 | 76.9±10.7 | 325.2±18.1 | 1.0±0.3 | 4.4±0.7 | 205.23±7.51 | 23.17±1.26 | |
| 试验组 | 72.7±26.6 | 324.8±17.7 | 2.3±1.9 | 4.7±1.4 | 132.52±5.92 | 58.44±8.59 | |
| t(Z)值 | 1.811 | -0.036 | 8.268 | 2.054 | -15.864 | 5.192 | |
| P值 | <0.001 | 0.977 | 0.017 | 0.026 | <0.001 | <0.001 |
| 变量 | 空腹C肽 | HbA1c | FPG | HOMA-IR | BMI | VFA | SFA | HDL-C | 血尿酸 | LDL-C | TC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| r(rs) | 0.050 | -0.580 | -0.590a | -0.230a | -0.510a | -0.370a | -0.270a | -0.260a | 0.205 | -0.011a | -0.026 |
| P值 | 0.590 | <0.001 | <0.001 | <0.050 | <0.001 | <0.010 | <0.010 | <0.010 | <0.010 | 0.884 | 0.733 |
| 变量 | TG | 收缩压 | 血肌酐 | 年龄 | 腰围 | 臀围 | 腰臀比 | 高血压 | 高脂血症 | 冠心病 | 脑梗死 |
| r(rs) | 0.012 | 0.012 | 0.097 | 0.032a | 0.091 | 0.089 | 0.015 | 0.042a | 0.057a | 0.018a | 0.026a |
| P值 | 0.875 | 0.743 | 0.207 | 0.461 | 0.712 | 0.381 | 0.622 | 0.196 | 0.727 | 0.622 | 0.837 |
Table 3 Correlation of Nesfatin-1 levels and indicator of glucose and lipid metabolism
| 变量 | 空腹C肽 | HbA1c | FPG | HOMA-IR | BMI | VFA | SFA | HDL-C | 血尿酸 | LDL-C | TC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| r(rs) | 0.050 | -0.580 | -0.590a | -0.230a | -0.510a | -0.370a | -0.270a | -0.260a | 0.205 | -0.011a | -0.026 |
| P值 | 0.590 | <0.001 | <0.001 | <0.050 | <0.001 | <0.010 | <0.010 | <0.010 | <0.010 | 0.884 | 0.733 |
| 变量 | TG | 收缩压 | 血肌酐 | 年龄 | 腰围 | 臀围 | 腰臀比 | 高血压 | 高脂血症 | 冠心病 | 脑梗死 |
| r(rs) | 0.012 | 0.012 | 0.097 | 0.032a | 0.091 | 0.089 | 0.015 | 0.042a | 0.057a | 0.018a | 0.026a |
| P值 | 0.875 | 0.743 | 0.207 | 0.461 | 0.712 | 0.381 | 0.622 | 0.196 | 0.727 | 0.622 | 0.837 |
| 变量 | 空腹C肽 | HbA1c | FPG | HOMA-IR | BMI | VFA | SFA | HDL-C | 血尿酸 | LDL-C | TC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| r(rs) | 0.140 | 0.460a | 0.410a | 0.240a | 0.430a | 0.500a | 0.300a | 0.150a | -0.274 | 0.066a | 0.003 |
| P值 | <0.050 | <0.001 | <0.001 | <0.001 | <0.050 | <0.010 | <0.010 | <0.050 | <0.010 | 0.391 | 0.965 |
| 变量 | TG | 血肌酐 | 年龄 | 腰围 | 臀围 | 腰臀比 | 高血压 | 高脂血症 | 冠心病 | 脑梗死 | |
| r(rs) | -0.038 | -0.049 | 0.021 | 0.016 | 0.014 | 0.052 | 0.021a | 0.035a | 0.018a | 0.008a | |
| P值 | 0.621 | 0.528 | 0.741 | 0.599 | 0.451 | 0.408 | 0.167 | 0.204 | 0.187 | 0.163 |
Table 4 Correlation of Ghrelin levels and indicator of glucose and lipid metabolism
| 变量 | 空腹C肽 | HbA1c | FPG | HOMA-IR | BMI | VFA | SFA | HDL-C | 血尿酸 | LDL-C | TC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| r(rs) | 0.140 | 0.460a | 0.410a | 0.240a | 0.430a | 0.500a | 0.300a | 0.150a | -0.274 | 0.066a | 0.003 |
| P值 | <0.050 | <0.001 | <0.001 | <0.001 | <0.050 | <0.010 | <0.010 | <0.050 | <0.010 | 0.391 | 0.965 |
| 变量 | TG | 血肌酐 | 年龄 | 腰围 | 臀围 | 腰臀比 | 高血压 | 高脂血症 | 冠心病 | 脑梗死 | |
| r(rs) | -0.038 | -0.049 | 0.021 | 0.016 | 0.014 | 0.052 | 0.021a | 0.035a | 0.018a | 0.008a | |
| P值 | 0.621 | 0.528 | 0.741 | 0.599 | 0.451 | 0.408 | 0.167 | 0.204 | 0.187 | 0.163 |
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| HbA1c<7% | 98 | 129.90±8.23 | 52.97±3.50 |
| 7%≤HbA1c≤9% | 47 | 137.11±9.36 | 58.30±2.30 |
| HbA1c>9% | 25 | 133.48±5.25 | 58.30±2.30 |
| F值 | 0.604 | 0.614 | |
| P值 | 0.548 | 0.542 |
Table 5 Analysis of variance of glycated hemoglobin with serum Nesfatin-1 and Ghrelin levels
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| HbA1c<7% | 98 | 129.90±8.23 | 52.97±3.50 |
| 7%≤HbA1c≤9% | 47 | 137.11±9.36 | 58.30±2.30 |
| HbA1c>9% | 25 | 133.48±5.25 | 58.30±2.30 |
| F值 | 0.604 | 0.614 | |
| P值 | 0.548 | 0.542 |
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 病程≤2年 | 38 | 122.90±10.91 | 58.30±6.76 |
| 2年<病程≤5年 | 72 | 120.48±8.62 | 66.76±5.93 |
| 5年<病程≤11年 | 43 | 124.18±10.54 | 54.97±5.54 |
| 病程>11年 | 17 | 109.09±9.27 | 60.09±5.83 |
| F值 | 0.701 | 0.821 | |
| P值 | 0.701 | 0.568 |
Table 6 Analysis of variance of diabetes duration and serum Nesfatin-1 and Ghrelin levels
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 病程≤2年 | 38 | 122.90±10.91 | 58.30±6.76 |
| 2年<病程≤5年 | 72 | 120.48±8.62 | 66.76±5.93 |
| 5年<病程≤11年 | 43 | 124.18±10.54 | 54.97±5.54 |
| 病程>11年 | 17 | 109.09±9.27 | 60.09±5.83 |
| F值 | 0.701 | 0.821 | |
| P值 | 0.701 | 0.568 |
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 糖尿病肾病 | 43 | 102.33±4.84 | 52.57±3.84 |
| 无糖尿病肾病 | 127 | 97.05±8.19 | 71.53±9.81 |
| t值 | -0.447 | 1.088 | |
| P值 | 0.656 | 0.278 |
Table 7 Relationship of diabetic nephropathy with serum Nesfatin-1 and Ghrelin levels
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 糖尿病肾病 | 43 | 102.33±4.84 | 52.57±3.84 |
| 无糖尿病肾病 | 127 | 97.05±8.19 | 71.53±9.81 |
| t值 | -0.447 | 1.088 | |
| P值 | 0.656 | 0.278 |
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 糖尿病视网膜病变 | 37 | 109.76±4.04 | 45.45±3.47 |
| 无糖尿病视网膜病变 | 133 | 96.32±4.56 | 49.85±3.51 |
| t值 | 2.115 | 0.768 | |
| P值 | 0.376 | 0.444 |
Table 8 Relationship of diabetic retinopathy with serum Nesfatin-1 and Ghrelin levels
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 糖尿病视网膜病变 | 37 | 109.76±4.04 | 45.45±3.47 |
| 无糖尿病视网膜病变 | 133 | 96.32±4.56 | 49.85±3.51 |
| t值 | 2.115 | 0.768 | |
| P值 | 0.376 | 0.444 |
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 糖尿病周围神经病变 | 61 | 96.15±7.85 | 61.98±5.71 |
| 无糖尿病周围神经病变 | 109 | 88.85±6.88 | 53.83±4.34 |
| t值 | -0.603 | -0.859 | |
| P值 | 0.548 | 0.394 |
Table 9 Relationship of diabetic peripheral neuropathy with serum Nesfatin-1 and Ghrelin levels
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 糖尿病周围神经病变 | 61 | 96.15±7.85 | 61.98±5.71 |
| 无糖尿病周围神经病变 | 109 | 88.85±6.88 | 53.83±4.34 |
| t值 | -0.603 | -0.859 | |
| P值 | 0.548 | 0.394 |
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 糖尿病周围血管病变 | 38 | 98.59±7.77 | 63.63±8.56 |
| 无糖尿病周围血管病变 | 132 | 95.42±6.97 | 59.06±4.98 |
| t值 | 0.159 | -0.438 | |
| P值 | 0.874 | 0.662 |
Table 10 Relationship analysis of diabetic peripheral vascular disease with serum Nesfatin-1 and Ghrelin levels
| 亚组 | 例数 | Nesfatin-1 | Ghrelin |
|---|---|---|---|
| 糖尿病周围血管病变 | 38 | 98.59±7.77 | 63.63±8.56 |
| 无糖尿病周围血管病变 | 132 | 95.42±6.97 | 59.06±4.98 |
| t值 | 0.159 | -0.438 | |
| P值 | 0.874 | 0.662 |
| [1] |
|
| [2] |
|
| [3] | |
| [4] |
|
| [5] |
|
| [6] |
|
| [7] | |
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
曹云婷,王玮. Nesfatin-1与糖代谢关系的研究进展 [J]. 中南大学学报(医学版),2024,49(6):832-838.
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
倪文娟,张宇诺,王玮. 双歧杆菌及绿茶对肥胖小鼠体质量及摄食因子的调节作用[J]. 疾病监测与控制,2023,17(6):421-425. DOI:10.19891/j.issn1673-9388.(2023)06-0421-05.
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [1] | XIAO Zhili, LU Chenxia, ZHU Hui, ZHANG Jia, CHEN Zhuangzhuang, SUN Wei, LIU Xiangchuxuan, LUO Cheng, XIAO Mingzhong, LI Xiaodong. Application and Future Prospects of CGM Technology in Co-management of MAFLD and T2DM [J]. Chinese General Practice, 2026, 29(31): 4521-4527. |
| [2] | TIAN Xiangyang, ZHOU Yingsheng, GAO Ying. Prospects of Behavioral and Lifestyle Interventions for Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(31): 4513-4520. |
| [3] | WEI Xuejuan, WANG Lihua, WANG Li, REN Jinglin, YAN Haiqing, YU Haiyang, LIU Jingfeng. Effectiveness of an Intelligent Voice Outbound Call System as an Adjunct to Usual Care for Health Management in Older Community-dwelling Patients with "Three Highs" Multimorbidity: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(31): 4635-4640. |
| [4] | LI Lan, LIU Lidi, ZHANG Peng, LI Dongze, YANG Ziyu, CHENG Yonglang, LIAO Xiaoyang, WAN Zhi. Lifestyle Intervention-based Weight Management: an Analysis of Key Highlights from the Partial Update of the 2025 NICE Guideline Overweight and Obesity Management (NG246) [J]. Chinese General Practice, 2026, 29(30): 4353-4359. |
| [5] | ZHAO Congjuan, JIN Tiantian, LIANG Jie, WANG Beining, GAO Yan. Comparative Effectiveness of GLP-1 Receptor Agonists on Patients with Diabetic Kidney Disease: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(29): 4326-4336. |
| [6] | FU Xiaoya, YANG Fei, GU Keyi, GU Handong, WANG Weiqiang. Correlation between Relative Fat Mass Index and Decreased Glomerular Filtration Rate in Patients with Cardiometabolic Comorbidities [J]. Chinese General Practice, 2026, 29(28): 4187-4192. |
| [7] | LU Hongrun, ZHANG Rui, ZHAO Yu, LI Jiazhen, WANG Weiqiang. Association of Cardiometabolic Comorbidity with Estimated Glomerular Filtration Rate [J]. Chinese General Practice, 2026, 29(28): 4179-4186. |
| [8] | ZHANG Han, CAI Genshen, FENG Zhengwen, ZHANG Kaiyue, LIAN Dongbo, ZHANG Hua, ZHANG Jing. Evaluating the Availability of Health Services for Obesity Comorbidities under Hierarchical Diagnosis and Treatment in Beijing: a Healthcare Institution Survey Study [J]. Chinese General Practice, 2026, 29(28): 4117-4124. |
| [9] | ZHANG Ying, TANG Yijun, LIU Lidi, JIANG Lihua, JIA Yu, YANG Rong, YANG Ziyu, LIAO Xiaoyang. Management of Cardiovascular Metabolic Risks in Obese Children and Adolescents in China: Based on the 2024 Italian Society of Pediatric Endocrinology and Diabetes Position Paper on Cardiometabolic Risk in Children and Adolescents with Obesity [J]. Chinese General Practice, 2026, 29(27): 3879-3887. |
| [10] | Expert Group on Guidelines for the Assessment, Treatment, and Prevention of Childhood Obesity in China, Professional Committee on Obesity Control in Women and Children, China Maternal and Child Health Research Association. Guidelines for the Assessment, Treatment, and Prevention of Childhood Obesity in China (Second Edition) [J]. Chinese General Practice, 2026, 29(23): 3233-3252. |
| [11] | LI Ge, ZHOU Yingsheng, TIAN Xiangyang, GAO Ying. Interpretation of the ACLM Clinical Practice Guideline: Lifestyle Interventions for the Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults [J]. Chinese General Practice, 2026, 29(22): 3086-3093. |
| [12] | HAN Congcong, QIU Xinyu, SHAN Chunfang, SONG Ning, CHEN Qingjie, MULADILI· Abudureheman, LI Xiaomei, YANG Yining, ZHAO Qian. Impact of Metabolic Obesity Phenotype on Long-term Prognosis after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2026, 29(21): 2950-2958. |
| [13] | ZHANG Ke, ZENG Xianchang, ZOLZAYA Enkhzaya, ZHU Yelin, HUANG Yiwen, LIU Zhenxiu, TAO Feng. Effect of Xiere Xingpi Yin on Eating Behaviors and Weight-related Outcomes in Patients with Obesity: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(20): 2759-2765. |
| [14] | WU Zhen, XI Yaqi, HU Linlin. Characteristics of Policy Instrument Selection and Combination for Weight Management in China: a Content Analysis of National Policy Documents (2016-2025) [J]. Chinese General Practice, 2026, 29(20): 2766-2774. |
| [15] | REYILAI· Maimaiti, ZHOU Yiran, WU Yun, LIU Zhencheng, LU Yaoqin, WU Haiyan. Association between Novel Obesity Indicators and Cardiovascular Disease Risk in Hypertensive Patients [J]. Chinese General Practice, 2026, 29(20): 2836-2845. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||